SMYD2 and SMYD3 regulate the MAPK pathway in pancreatic cancer

Version française

SMYD2 and SMYD3 are lysine methyltransferases. SMYD2 monomethylates the stress response kinase MAPKAPK3 at Lys355. SMYD3 methylates MAP3K2 at K260. Both of these modifications result in increased activity of the respective kinases. In the case of MAPKAPK3 this is thought to be due to decreased protein turnover and therefore higher effective concentration in the cytoplasm. In the case of MAP3K2 the methylation is known to cause the dissociation of the inhibitor protein PP2A [1,2]. SMYD2 and SMYD3 have other protein targets which are relevant to cancer such as p53.

The activation of both kinases promotes pancreatic cancer cell growth. SMYD3 inhibition by small molecule has been shown to inhibit the growth of a wide range of cancers including pancreatic cancer in preclinical animal models [3]. SMYD2 small molecule inhibitors have been developed however they have only been tested in vitro [4]. Combination with MAP kinase inhibitors such as MEK and ERK may prove effective.

Refs

  1. Reynoird, Nicolas, Pawel K. Mazur, Timo Stellfeld, Natasha M. Flores, Shane M. Lofgren, Scott M. Carlson, Elisabeth Brambilla, et al. ‘Coordination of Stress Signals by the Lysine Methyltransferase SMYD2 Promotes Pancreatic Cancer’. Genes & Development, 17 March 2016. doi:10.1101/gad.275529.115.
  2. Mazur, Pawel K., Nicolas Reynoird, Purvesh Khatri, Pascal W. T. C. Jansen, Alex W. Wilkinson, Shichong Liu, Olena Barbash, et al. ‘SMYD3 Links Lysine Methylation of MAP3K2 to Ras-Driven Cancer’. Nature 510, no. 7504 (21 May 2014): 283–87. doi:10.1038/nature13320.
  3. Peserico, Alessia, Aldo Germani, Paola Sanese, Armenio Jorge Barbosa, Valeria di Virgilio, Raffaella Fittipaldi, Edoardo Fabini, et al. ‘A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth’. Journal of Cellular Physiology 230, no. 10 (October 2015): 2447–60. doi:10.1002/jcp.24975.
  4. Nguyen, Hannah, Abdellah Allali-Hassani, Stephen Antonysamy, Shawn Chang, Lisa Hong Chen, Carmen Curtis, Spencer Emtage, et al. ‘LLY-507, a Cell-Active, Potent, and Selective Inhibitor of Protein-Lysine Methyltransferase SMYD2’. Journal of Biological Chemistry 290, no. 22 (29 May 2015): 13641–53. doi:10.1074/jbc.M114.626861.

 

Advertisements

Galectin-3 (LGALS3) upregulated in pancreatic cancer

Gal3

Gal3-panc

Figure 1: Top panel: Galectin-3 is highly expressed in the 44 pancreatic cancer cell lines in the CCLE. CDKN2A is included for reference. Bottom panel: An analysis of galectin-3 expression from microarray gene-expression profiles of 45 matching pairs of pancreatic tumor and adjacent non-tumor tissues from 45 patients with pancreatic ductal adenocarcinoma (PDAC) (GEO Series GSE28735). RMA = robust multi-array average (mRNA expression).

See also the pancreatic cancer database for papers – here.

GITR checkpoint antibody in combination with pancreatic cancer vaccine showed tumour rejection in preclinical model

Version française

GITR (glucocorticoid-induced tumor necrosis factor receptor) is an immune checkpoint cell surface receptor induced within 24-72h on naïve T cells upon engagement with an antigen presenting cell [1]. When GITR engages with its ligand GITR-L effector T cell proliferation is induced. In the pancreatic cancer microenvironment there is a shortage of GITR-L. Therefore one way to improve immune response is with GITR activating antibodies.

In a well known analogy, checkpoint antibodies take the breaks off the immune system, however in the case of pancreatic cancer because it is non-immunogenic, the clinician must also put their foot down so to speak. Mesothelin is a membrane bound glycoprotein that is universally overexpressed in pancreatic cancer. In a preclinical mouse model of pancreatic cancer full length human mesothelin cDNA was used as a vaccine in combination with activating GITR antibodies [2]. In GITR antibody alone treated tumours all remained. In mesothelin alone treated tumours half were eliminated and in GITR antibody and vaccine treated mice 94% had eliminated tumours. This strikingly demonstrates the power of the combination of pancreatic cancer vaccines with immune checkpoint antibodies.

A mesothelin vaccine in combination with GM-CSF immune system stimulation has successfully completed phase II clinical trial [3]. Merck, Bristol-Myers Squibb, and Pfizer are developing GITR antibodies.

Refs

  1. Schaer, David A, Judith T Murphy, and Jedd D Wolchok. ‘Modulation of GITR for Cancer Immunotherapy’. Current Opinion in Immunology 24, no. 2 (April 2012): 217–24. doi:10.1016/j.coi.2011.12.011.
  2. Gaffney, Mary C., Peter Goedegebuure, Hiroyuki Kashiwagi, John R. Hornick, Reuben I. Thaker, Timothy Eberlein, and William G. Hawkins. ‘DNA Vaccination Targeting Mesothelin Combined with Anti-GITR Antibody Induces Rejection of Pancreatic Adenocarcinoma’. Cancer Research 66, no. 8 Supplement (15 April 2006): 329–329. http://cancerres.aacrjournals.org/content/66/8_Supplement/329.2.
  3. ‘Clinical Trials | Aduro Biotech’. Accessed 22 March 2016. http://www.aduro.com/pipeline/clinical-trials/.

Mutant RAS vaccine showed trend for improved survival in a subset of pancreatic cancer patients

Version française

The GI-4000 vaccine is built from the tarmogen platform [1]. Tarmogens are heat inactivated yeast which contain overexpressed proteins. In the case of GI-4000 they contain peptides of mutated RAS. The KRAS gene is mutated in 90% of pancreatic cancers. In a phase II trial GI-4000 showed a trend towards improved survival in a subset of pancreatic cancer patients, those with post-operative residual disease [2].

From biopsies of this patient subset a biomarker companion diagnostic was developed retrospectively by MALDI-TOF mass spectrometry that can identify pancreatic cancer patients as likely to respond to GI-4000 [2]. In theory this could be converted to a next generation sequence based diagnostic and this may become a cheaper option as sequencing costs continue to fall. A phase III trial to confirm or refute the effectiveness of GI-4000 in patients identified as eligible by the companion diagnostic remains to be carried out. The potential for combination with checkpoint inhibitors which theoretically should be highly synergistic with the mechanism of action of GI-4000 are no doubt also under consideration.

Refs

  1. ‘GlobeImmune’s $69M IPO Designed to Build Immunotherapy Pipeline – FierceBiotech’. Accessed 21 March 2016. http://www.fiercebiotech.com/story/globeimmunes-69m-ipo-designed-build-immunotherapy-pipeline/2012-07-03.
  2. Richards, Donald A., Peter Muscarella, Tanios Bekaii-Saab, Lalan S. Wilfong, Vic Velanovich, Julian Raynov, Patrick J. Flynn, et al. ‘Abstract 5314: A Proteomic Signature Predicts Response to a Therapeutic Vaccine in Pancreas Cancer; Analysis from the GI-4000-02 Trial’. Cancer Research 74, no. 19 Supplement (10 January 2014): 5314–5314. doi:10.1158/1538-7445.AM2014-5314.

Hyaluronidase treatment of high HA pancreatic cancer increased progression-free survival

Version française

The glycosaminoglycan hyaluronan (HA) is a major component of the extracellular matrix (ECM). Data from a recent phase II trial suggest that 25-36% of tumours from stage IV previously untreated pancreatic cancer patients have high levels of HA [1]. It is thought that HA can act as a barrier preventing drug penetrance. Hyaluronidase is an enzyme that degrades HA and preliminary data suggests that a systemically delivered formulation of the enzyme can increase overall survival time of late stage pancreatic cancer patients expressing high levels of HA (HAhigh) when combined with nab-paclitaxel and gemcitabine compared with nab-paclitaxel and gemcitabine alone [2].

It is important to note that due to unavoidable low patient numbers this is only a trend, however subsequent phase III clinical trials will confirm or refute the trend. Increased progression-free survival of HAhigh patients was statistically significant. The stratification of HA status was performed retrospectively and suggests that for future trials eligibility should be determined based on HA status. This is an important strategy that is relevant to all pancreatic cancer therapeutics in development. In the era of next generation sequencing it is important to gather as much patient tumour data as possible with the goal of uncovering biomarkers of efficaciousness which can be used to select patients for future clinical trials.

The importance of HA status necessitated the development of a companion diagnostic. Hyaluronidase can potentially increase drug penetrance and efficaciousness in a subset of pancreatic cancer patients.

Refs

  1. ‘High Response Rate and PFS with PEGPH20 Added to Nab-Paclitaxel/gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase II Study.’ Accessed 17 March 2016. http://meetinglibrary.asco.org/print/1991286.
  2. ‘Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-Free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients’. Accessed 17 March 2016. http://www.streetinsider.com/Press+Releases/Halozyme+Phase+2+Clinical+Study+Of+Investigational+Drug+PEGPH20+Shows+Doubling+Of+Progression-free+Survival+And+Improvement+Trend+In+Overall+Survival+In+High+HA+Metastatic+Pancreatic+Cancer+Patients/10609719.html.

Targeting paclitaxel to the pancreas with a biodegradable drug-eluting device

Version française

The cremaphor formulation of paclitaxel has dose limiting toxicity which prevent its use for pancreatic cancer. Paclitaxel’s toxicity like the majority of chemotherapeutics stems from its systemic delivery and toxicity to normal cells. However recently an albumin-bound formulation (nab-paclitaxel) has demonstrated increased survival times in combination with gemcitabine compared to gemcitabine alone [1]. And now a new biodegradable device has been developed which can deliver chemotherapeutics including paclitaxel directly to the pancreas limiting systemic toxicities [2].

The device has been tested with paclitaxel and shown favourable results in mouse xenograft models over systemically delivered paclitaxel. The device is flexible and can be surgically placed over the pancreatic tumour where it rests delivering a steady flow of paclitaxel for the duration of the treatment. The one time insertion is an attractive aspect compared with repeated intravenous deliveries.

Improving delivery and dosing of existing pancreatic cancer chemotherapeutics is a growing area of commercial research. Devices under development include an implantable electroporation device (see here) and encapsulated 293 cells that activate prodrug-chemotherapeutics (see here). Another approach uses low dose chemotherapy to take advantage of pancreatic cancer heterogeneity to maintain stable disease (see here).

Refs

  1. Ma, W. W., and M. Hidalgo. ‘The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer’. Clinical Cancer Research 19, no. 20 (15 October 2013): 5572–79. doi:10.1158/1078-0432.CCR-13-1356.
  2. Ligorio, Matteo, Laura Indolfi, David T. Ting, Kristina Xega, Nicola Aceto, Francesca Bersani, Cristina R. Ferrone, et al. ‘Abstract 4584: A Novel Drug-Eluting Platform for Localized Treatment of Pancreatic Cancer’. Cancer Research 74, no. 19 Supplement (10 January 2014): 4584–4584. doi:10.1158/1538-7445.AM2014-4584.

Renalase is over-expressed and activates STAT3 in pancreatic cancer

Version française

Renalase (RNLS) is a secreted flavoprotein. It is over-expressed by pancreatic cancer and acts as a survival factor blocking apoptosis. Importantly RNLS activates STAT3 and establishes a positive feedback loop whereby STAT3 promotes greater RNLS expression [1].

STAT3 plays a major role in pancreatic cancer [2]. It will be very important to determine through further research the extent to which STAT3 mediates renalase’s pro-cancer effects. A combination of renalase and STAT3 inhibition may prove effective against pancreatic cancer. A STAT3 inhibitor is already in clinical trials [3].

As renalase is secreted it may also serve as a useful diagnostic blood biomarker of pancreatic cancer (See here for pancreatic cancer biomarkers under development). This is certainly worth pursuing as late detection is a major reason for the dismal outcomes of pancreatic cancer patients.

Refs

  1. Guo, Xiaojia, Lindsay Hollander, Douglas MacPherson, Ling Wang, Heino Velazquez, John Chang, Robert Safirstein, Charles Cha, Fred Gorelick, and Gary V. Desir. ‘Inhibition of Renalase Expression and Signaling Has Antitumor Activity in Pancreatic Cancer’. Scientific Reports 6 (14 March 2016): 22996. doi:10.1038/srep22996.
  2. Corcoran, R. B., G. Contino, V. Deshpande, A. Tzatsos, C. Conrad, C. H. Benes, D. E. Levy, J. Settleman, J. A. Engelman, and N. Bardeesy. ‘STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis’. Cancer Research 71, no. 14 (15 July 2011): 5020–29. doi:10.1158/0008-5472.CAN-11-0908.
  3. Hong, David, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, et al. ‘AZD9150, a next-Generation Antisense Oligonucleotide Inhibitor of STAT3 with Early Evidence of Clinical Activity in Lymphoma and Lung Cancer’. Science Translational Medicine 7, no. 314 (18 November 2015): 314ra185. doi:10.1126/scitranslmed.aac5272.